Is entyvio an iv infusion or a subcutaneous injection?

Primary Administration Method for Entyvio

Entyvio (vedolizumab) is given as an intravenous (IV) infusion. The standard induction regimen involves IV infusions at weeks 0, 2, and 6, followed by maintenance infusions every 8 weeks.[1]

Subcutaneous Injection Option

A subcutaneous (SC) injection formulation of Entyvio was FDA-approved in 2023 for maintenance treatment after initial IV induction. Patients can switch to SC self-injections (108 mg weekly or 108 mg every 2 weeks) for ongoing use in ulcerative colitis or Crohn's disease.[1][2]

How Treatment Schedules Compare

• IV route: Administered in a clinic or hospital; each infusion takes about 30 minutes.
  
• SC route: Self-administered at home with a prefilled syringe or autoinjector after the first doses via IV.
  This SC option improves convenience but requires at least two IV doses first.[1]
  
  

Who Qualifies for SC Entyvio

SC is for adults responding to initial IV therapy. It's not approved as a starting treatment. Dosing flexibility allows weekly or biweekly SC shots based on patient needs and doctor guidance.[2]

Sources
[1]: Entyvio Prescribing Information (FDA)
[2]: Takeda Press Release on SC Approval